Many details of these agreements remain undisclosed, but what we know suggests they may be less far-reaching than claimed.

Understanding the impact of price controls on drug research and approvals of secondary indications is critical for policy ...

What California chooses in the next six months will determine whether a decade of Medicaid transformation holds or collapses ...

The current MA risk adjustment model has shortcomings, both in predictive accuracy and payment equity across the Medicare ...

Since 1971, protection against measles, mumps, and rubella has been delivered in a single combined injection. A proposal to ...

Pediatrics is increasingly moving toward regionalized hub-and-spoke models organized around comprehensive “centers of ...

The administration is expected to appeal at least parts of the ruling, but the timing and scope of appeal is unclear. Meanwhile, HHS may offer flexibility on the current August 12 deadline for ...

Unless overturned, the Mizner decision will hamper efforts in Colorado and other states to implement prescription drug affordability boards. The Federal Circuit may use the case to clarify the ...

The premise of Medicaid as a policy laboratory rests on generating knowledge through rigorous evaluation. Yet, too often, ...

Under the FDA’s regulatory authority, drug companies, prescribers, and patients operate under one national standard for drug ...

Without data that support plan level evaluation, accountability for Medicare Advantage dental benefits remains aspirational rather than operational.

If all states adopt the Immigrant Children’s Health Improvement Act in the next few months, more lawfully residing immigrant children and pregnant women, such as refugees, could retain their ...